*The only approved and recommended dose for dimethyl fumarate is 240 mg BID.4
Primary
Proportion of patients relapsed (PPR)
Additional
Experienced at least 1 relapse over the year preceding the trial
OR
Had a brain magnetic resonance imaging (MRI) scan demonstrating at least 1 gadolinium-enhancing (Gd+) lesion within 6 weeks of randomization
AND
An Expanded Disability Status Scale (EDSS) score ranging from 0 to 5
*Please see full Prescribing Information for additional information.
Neurological evaluations
Performed at baseline, every 3 months, and at time of suspected relapse
MRI evaluations
Performed in 44% of patients at baseline, month 6, and years 1 and 2
69% of patients treated with dimethyl fumarate BID completed 96 weeks of treatment compared to 65% of patients taking placebo1
*The only approved and recommended dose for dimethyl fumarate is 240 mg BID.4
Primary
Annualized relapse rate (ARR)
Additional
Experienced at least 1 relapse over the year preceding the trial
OR
Had a brain magnetic resonance imaging (MRI) scan demonstrating at least 1 gadolinium-enhancing (Gd+) lesion within 6 weeks of randomization
AND
An Expanded Disability Status Scale (EDSS) score ranging from 0 to 5
*Please see full Prescribing Information for additional information.
Neurological evaluations
Performed at baseline, every 3 months, and at time of suspected relapse
MRI evaluations
Performed in 48% of patients at baseline, month 6, and years 1 and 2
70% of patients treated with dimethyl fumarate BID completed 96 weeks of treatment compared to 64% of patients taking placebo1